Remyelination in multiple sclerosis

Hans Lassmann, Wolfgang Brück, Claudia Lucchinetti, Moses Rodriguez

Research output: Contribution to journalArticlepeer-review

147 Scopus citations


Stimulation of remyelination in multiple sclerosis lesions may be one possible therapeutic approach. However, since the pathology and pathogenesis of multiple sclerosis may be heterogeneous, it is important to analyze in what patients and at what stages of the disease such a therapy can be reasonable and feasible. Spontaneous remyelination is pronounced in some MS patients. The extent of remyelination correlates well with the presence of oligodendrocytes in the lesions. Yet the source and origin of the remyelinating cells is still unclear. These may be derived from either undifferentiated progenitor cells or, in part from mature oligodendrocytes, that have escaped destruction during lesional activity. Complete remyelination of plaques is possible, leading to the formation of 'shadow plaques'. No reliable data are available at present on the frequency of remyelination in different forms of MS. However, most studies agree that remyelination is especially prominent at the early stages of the disease, whereas it is sparse after several years of disease duration. In addition, very little remyelination is found in cases of primary progressive MS.

Original languageEnglish (US)
Pages (from-to)133-136
Number of pages4
JournalMultiple Sclerosis
Issue number2
StatePublished - Apr 1997


  • Demyelination
  • Oligodendrocytes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Remyelination in multiple sclerosis'. Together they form a unique fingerprint.

Cite this